Special Issue "In-Depth Exploration of Immuno-Oncology and Engineering Immune Cells to Kill Cancer Cells"
A special issue of Hematology Reports (ISSN 2038-8330).
Deadline for manuscript submissions: 27 March 2024 | Viewed by 360
Interests: chimeric antigen receptor; NK and T cell engagers; bispecific antibody
Interests: acute lymphoblastic leukemia; acute myeloid leukemia; myelodysplastic syndromes; multiple myeloma and MGUS; non-Hodgkin and Hodgkin lymphoma
Special Issues, Collections and Topics in MDPI journals
Special Issue in International Journal of Molecular Sciences: Novel Agents and Mechanisms in Acute Leukemias
Special Issue in International Journal of Molecular Sciences: Novel Therapeutics and Therapeutic Resistance in Hematological Malignancy
Special Issue in International Journal of Molecular Sciences: Novel Agents and Mechanisms in Acute Leukemias 2.0
Special Issue in Hematology Reports: Stem Cell Transplantation in Cancer Treatment: Current Status and Future Direction
Special Issue in Hematology Reports: Opportunities and Challenges in Multiple Myeloma Treatment and Management
Special Issue in Cancers: Multiple Myeloma and Bone Marrow Microenvironment
Special Issue in Hematology Reports: State of the Art Papers from 'The Society of Hematologic Oncology Italy – SOHO ITALY'
Special Issue in Journal of Clinical Medicine: How to Treat and Manage Multiple Myeloma in the Era of Ultra-Novel Agents
Special Issue in Hematology Reports: Diagnosis and Management of Acute Leukemia(AML, ALL): Drafting from Molecular Mechanisms to Clinical Practice
Special Issue in Cells: CD38 in Basic Science: Reflecting on the Past to Move to the Future
Special Issue in Hematology Reports: State of the Art Papers from the XXXI IACRLD Symposium
Topics: Leukemia-Challenges and Current Treatment Options
Immune system protects the body from infection and disease. Cancer is a kind of disease that outsmarts the body's immune system and evades its defenses. In most cases, it doesn't show up until it is too late to do anything about it. In recent years, advances in cancer immunotherapy have improved immune system's ability to fight cancer. Despite this, it has some complications and uncertainty, as it can destroy healthy cells. Due to recent developments in targeted immunotherapy, adverse effects of cellular immunotherapy may be reduced, and patient survival might be improved. This special issue will publish original research articles and reviews demonstrating the impact of targeted specific engineered immune cells (Bispecific, BITE, Engagers) in the clinical management of hematologic malignancies.
Dr. Anudishi Tyagi
Dr. Claudio Cerchione
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Hematology Reports is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- hematological malignancies
- monoclonal antibody
- CAR-T/NK cells
- bispecific T and NK cells engagers
- tumor infiltrating lymphocyte (TIL) therapy
- cytokine therapy